预约演示
更新于：2025-08-23
Ganirelix Acetate
醋酸加尼瑞克
更新于：2025-08-23
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-07-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C82H117ClN18O15 |
InChIKeyBNXQPWOTZJCGRG-FEGBTNLQSA-N |
CAS号129311-55-3 |
Sequence Code 525016563
关联
50
项与 醋酸加尼瑞克 相关的临床试验NCT06745466
Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women
NCT06481696
Randomized, Placebo-controlled, Double-blind, Single-center Trial to Evaluate the Possible Action of Resveratrol in Improving the Outcomes of Controlled Ovarian Stimulation During the IVF/ICSI Cycles in Couples With Unexplained Infertility
NCT05751252
Short-term GnRH- Antagonist Treatment to Lower LH Pulsatility in Women With PCOS Aiming to Improve Hormonal Functions
100 项与 醋酸加尼瑞克 相关的临床结果
登录后查看更多信息
100 项与 醋酸加尼瑞克 相关的转化医学
登录后查看更多信息
100 项与 醋酸加尼瑞克 相关的专利（医药）
登录后查看更多信息
415
项与 醋酸加尼瑞克 相关的文献（医药）2025-05-01REPRODUCTIVE BIOMEDICINE ONLINE
Freeze-all indications in women with subfertility undergoing IVF: a cohort study
Article
作者: Álvarez Pinochet, Claudio ; Fontes Jiménez, Juan ; Augé, Elisabet ; Ordóñez Pérez, Daniel ; Doménech, Alejandro ; Fernández-Sánchez, Manuel ; Ferrando Serrano, Marcos ; Torres Vives, Margarita ; Reche Rosado, Alberto ; Moens, Véronique ; García-Velasco, Juan Antonio ; Muñoz, Elkin
RESEARCH QUESTION:
How widely is the freeze-all strategy implemented in clinical practice, and what are its indications?
DESIGN:
This multicentre, prospective observational study included women aged ≥18 years with subfertility and a clinical indication for IVF or intracytoplasmic sperm injection (ICSI) across 24 Spanish assisted reproductive treatment (ART) centres. Patients were included between February 2021 and July 2022, and followed-up until confirmation of pregnancy (ongoing pregnancy, ≥20 weeks) or 6 months after cryopreservation. The primary endpoint was the proportion of patients who cryopreserved all available embryos and the main indications.
RESULTS:
The population comprised 1034 evaluable women (mean ± SD age 36.3 ± 4.1 years). The main causes of subfertility were male factor (301/1034, 29.1%) and maternal age (277/1034, 26.8%). Ovarian stimulation with FSH plus highly purified urinary human menopausal gonadotrophin/LH was performed in 466/906 (51.4%) women. For pituitary down-regulation, most women (704/881, 79.9%) received the gonadotrophin-releasing hormone antagonist ganirelix. The freeze-all strategy was indicated in 794 (78.1%) patients, with the most common reasons being planned preimplantation genetic testing (490/794, 61.7%) and risk of ovarian hyperstimulation syndrome (192/794, 24.2%). Of the 709 first embryo transfers analysed, 132 (18.6%) were fresh embryo transfers and 577 (81.4%) were frozen embryo transfers. By the third embryo transfer, the cumulative rates of clinical and ongoing pregnancy per embryo transfer were 72.2% (436/604) and 62.9% (317/504), respectively.
CONCLUSIONS:
The preferred treatment strategy in the study cohort was to freeze all available embryos, mainly because of planned preimplantation genetic testing and to avoid the risk of ovarian hyperstimulation syndrome.
2025-04-01HUMAN REPRODUCTION
Reduction in minipubertal gonadotropin levels alters reproductive lifespan and ovarian follicular loss in female mice
Article
作者: Souaré, Fatoumata ; Giton, Frank ; Naulé, Lydie ; Quintas, Daniel ; Airaud, Éloïse ; Chester, Mélanie ; Corre, Raphaël ; Mhaouty-Kodja, Sakina ; Devillers, Marie M ; Guigon, Céline J ; Petrovic, Claire-Hélène
Abstract:
STUDY QUESTION:
What is the effect of attenuating the physiological hypergonadotropic activity encountered at minipuberty on female reproductive function in a mouse model?
SUMMARY ANSWER:
Decreasing the surge of gonadotropins at minipuberty extended reproductive lifespan, coinciding with alterations in neuroendocrine and ovarian aging.
WHAT IS KNOWN ALREADY:
Minipuberty is characterized by the tremendous activation of the gonadotrope axis, as evidenced by elevated levels of gonadotropins regulating folliculogenesis and the synthesis of ovarian hormones, but its role in fertility remains unclear.
STUDY DESIGN, SIZE, DURATION:
To determine the link between gonadotrope axis activity at minipuberty and reproductive parameters, we used a pharmacological approach to suppress gonadotropin levels in Swiss mice by injecting daily a GnRH receptor antagonist (GnRHR) (Ganirelix, 10 µg/mouse) or its vehicle between 10 and 16 postnatal days, to cover the entire duration of minipuberty. We analyzed the onset of puberty and estrous cyclicity as well as fertility in young (3–5 months) and middle-aged (11 months) mice from control (CTR) and antagonist-treated groups (n = 17–20 mice/age and treatment group). Ovaries and brains were collected, fixed, and sectioned (for histology, follicle count, and immunohistochemistry) or frozen (for analysis of follicular markers, aging, and inflammation) from adult females, and blood was collected by cardiac puncture for hormonal assays (n = 3–8 mice/age and treatment group).
PARTICIPANTS/MATERIALS, SETTING, METHODS:
To analyze the initiation of puberty, we monitored vaginal opening and performed vaginal smears in CTR and antagonist-treated mice. We studied estrous cyclicity on vaginal smears at the beginning of reproductive life. Mice were mated several times with males to assess fertility rates, delay of conception, and litter size. To evaluate ovarian function, we counted follicles at different stages and corpora lutea, and we determined the relative intra-ovarian abundance of key follicular markers by real-time RT-PCR, as well as the levels of circulating anti-Müllerian hormone (AMH) and progesterone by ELISA and GC-MS, respectively. We also analyzed features of ovarian aging and inflammation by histology and by measuring the relative intra-ovarian abundance of some markers using real-time RT-PCR. To determine the impact on neuroendocrine determinants related to the CTR of reproduction, we analyzed circulating gonadotropin levels using Luminex assays as well as kisspeptin and GnRH immunoreactivity in the hypothalamus by immunohistochemistry.
MAIN RESULTS AND THE ROLE OF CHANCE:
Our results show that the treatment had no impact on the initiation of puberty, estrous cyclicity, or fertility at the beginning of reproductive life. However, it increased reproductive lifespan, as shown by the higher percentage of antagonist-treated females than CTRs still fertile at 11 months of age (33% versus 6%; P = 0.0471). There were no significant differences in the number of kisspeptin and GnRH neurons, nor in the density of kisspeptin- and GnRH-immunoreactive neurons in the hypothalamic areas involved in reproduction between the two groups of mice studied at either 4 or 11 months. In addition, basal levels of FSH were comparable between the two groups at 4 and 11 months, but not those of LH at 11 months which were much lower in females treated with antagonist than in their age-matched CTRs (237 ± 59.6 pg/ml in antagonist-treated females versus 1027 ± 226.3 pg/ml in CTRs, P = 0.0069). Importantly, at this age, antagonist-treated mice had basal LH levels comparable to young mice (e.g. in 4-month-old CTRs: 294 ± 71.75 pg/ml, P > 0.05). Despite their prolonged reproductive lifespan and delayed neuroendocrine aging, antagonist-treated mice exhibited earlier depletion of their follicles, as shown by lower numbers of primordial, primary, and preantral follicles associated with lower circulating AMH levels and relative intra-ovarian abundance of Amh transcripts than CTR mice. However, they exhibited comparable completion of folliculogenesis, as suggested by the numbers of antral follicles and corpora lutea, relative intra-ovarian abundance of Cyp19a1, Inhba, and Inhbb transcripts, and circulating progesterone levels that all remained similar to those of the CTR group. These observed alterations in ovarian function were not associated with increased ovarian aging or inflammation.
LARGE-SCALE DATA:
None.
LIMITATIONS, REASONS FOR CAUTION:
This study was carried out on mice, which is a validated research model. However, human research is needed for further validation.
WIDER IMPLICATIONS OF THE FINDINGS:
This study, which is the first to investigate the physiological role of minipuberty on reproductive parameters, supports the idea that suppressing the high postnatal levels of gonadotropins may have long-term effects on female fertility by extending the duration of reproductive life. Perturbations in gonadotropin levels during this period of life, such as those observed in infants born prematurely, may thus have profound consequences on late reproductive functions.
STUDY FUNDING/COMPETING INTEREST(S):
This research was conducted with the financial support of ANR AAPG2020 (ReproFUN), CNRS, Inserm, Université Paris Cité, and Sorbonne Université. The authors declare that they have no conflicts of interest.
2025-01-21The Journal of clinical endocrinology and metabolism
Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF
Article
作者: Merhi, Zaher ; Mouanness, Marco
Abstract:
Background:
The injectable gonadotropin-releasing hormone (GnRH) antagonists have traditionally been used for ovulation suppression during controlled ovarian hyperstimulation for in vitro fertilization (IVF), leading to increased painful daily injections and cost. The use of the oral GnRH antagonist elagolix for ovulation suppression in IVF has not been studied.
Methods:
This retrospective cohort study of patients undergoing IVF who received either oral elagolix 50 mg every other day or ganirelix/cetrotide injection daily for ovulation suppression during controlled ovarian hyperstimulation included 269 patients, 173 in the elagolix group and 96 in the ganirelix/cetrotide group. The main outcome was the suppression of luteinizing hormone (LH) blood levels, reflecting ovulation suppression.
Results:
Age, body mass index, anti-Müllerian hormone, baseline follicle-stimulating hormone, antral follicles count, dose of medications used, number of days of ovarian stimulation, and peak estradiol (E2) levels were similar in both groups. When blood LH and E2 levels were measured before intake and the day after intake of either elagolix or ganirelix/cetrotide, both groups had significant and similar drop in LH levels and increase in E2 levels. When comparing IVF cycle outcomes in both groups, the number of oocytes retrieved, number of mature oocytes, fertilization rate, blastocyst formation rate, euploidy rate, and endometrial lining thickness at the time of the trigger were all similar.
Conclusion:
Oral GnRH antagonist, a much cheaper and less invasive medication that is used at a lower frequency, showed comparable ovulation suppression to the costly injectable GnRH antagonist. Further studies are required to evaluate the effect of oral GnRH antagonist on endometrial lining receptivity and pregnancy outcomes, especially when using fresh embryo transfer IVF protocols.
100 项与 醋酸加尼瑞克 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 女性不孕症 | 日本 | 2008-07-16 | |
| 卵巢过度刺激综合征 | 欧盟 | 2000-05-16 | |
| 卵巢过度刺激综合征 | 冰岛 | 2000-05-16 | |
| 卵巢过度刺激综合征 | 列支敦士登 | 2000-05-16 | |
| 卵巢过度刺激综合征 | 挪威 | 2000-05-16 | |
| 早产 | 美国 | 1999-07-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 30 | (Delayed Start) | 糧蓋齋網醖願繭窪網艱(簾獵簾獵鑰壓鹹壓蓋構) = 壓製糧鏇艱願齋顧願齋 觸繭願選膚鹽願襯鏇範 (廠鑰遞糧壓築築積壓積, 鹹鹽選構夢構鑰範艱獵 ~ 廠夢艱憲鑰顧憲顧糧築) 更多 | - | 2021-06-15 | ||
(Conventional Start) | 糧蓋齋網醖願繭窪網艱(簾獵簾獵鑰壓鹹壓蓋構) = 簾鹹網餘鹹衊壓淵選膚 觸繭願選膚鹽願襯鏇範 (廠鑰遞糧壓築築積壓積, 選淵願網鏇壓憲餘壓壓 ~ 願繭艱壓願襯壓齋網憲) 更多 | ||||||
N/A | 155 | 襯範觸齋鹹壓願願繭艱(築餘衊顧鏇鹹築淵艱築) = 積夢顧範餘築糧遞膚壓 鬱觸願繭繭鬱蓋鏇淵醖 (顧壓窪願簾積艱醖窪觸, 0.27) 更多 | - | 2020-12-24 | |||
Ganirelix acetate+Transdermal placebo patch (Pre2) | 襯範觸齋鹹壓願願繭艱(築餘衊顧鏇鹹築淵艱築) = 壓廠襯憲觸窪齋遞蓋窪 鬱觸願繭繭鬱蓋鏇淵醖 (顧壓窪願簾積艱醖窪觸, 0.18) 更多 | ||||||
临床3期 | - | 259 | 選壓艱觸築壓蓋積鏇蓋(齋繭顧壓遞餘膚鹹構積) = 觸壓淵壓鑰鹽積顧窪鏇 襯夢積窪築鹹遞廠齋衊 (簾繭蓋憲鏇鏇製鹹糧鹹 ) | - | 2012-10-01 | ||
選壓艱觸築壓蓋積鏇蓋(齋繭顧壓遞餘膚鹹構積) = 襯構鹽衊齋齋繭憲襯鑰 襯夢積窪築鹹遞廠齋衊 (簾繭蓋憲鏇鏇製鹹糧鹹 ) | |||||||
临床4期 | 173 | (Menopur/Endometrin) | 鹹遞製鏇繭鬱蓋醖網遞 = 夢選餘廠鹽艱構壓構鹹 網齋齋獵簾製顧選簾選 (糧齋網壓艱鑰醖積觸夢, 餘繭蓋獵壓獵夢鹽顧遞 ~ 糧鑰範積壓積選繭積構) 更多 | - | 2011-08-30 | ||
(Menopur/Progesterone in Oil) | 鹹遞製鏇繭鬱蓋醖網遞 = 淵鹹築網繭淵憲願鑰膚 網齋齋獵簾製顧選簾選 (糧齋網壓艱鑰醖積觸夢, 鬱窪觸餘築夢蓋窪積艱 ~ 鏇膚鏇選夢膚選窪鑰願) 更多 | ||||||
N/A | 1,000 | 齋觸糧鹽築襯膚蓋壓獵(築獵網鑰網顧鑰醖願齋) = 鏇膚鬱壓糧鹹繭遞獵醖 顧鏇獵築選夢鑰顧蓋醖 (壓願鬱範窪構遞襯網簾 ) | - | 2010-06-01 | |||
GnRH agonist (buserelin) | 齋觸糧鹽築襯膚蓋壓獵(築獵網鑰網顧鑰醖願齋) = 製鹽構廠廠窪艱齋淵淵 顧鏇獵築選夢鑰顧蓋醖 (壓願鬱範窪構遞襯網簾 ) | ||||||
临床3期 | 259 | human chorionic gonadotropin (hCG) (Ganirelix) | 糧齋餘鏇衊鏇醖遞淵築(衊窪襯構齋鏇憲衊齋構) = 觸築艱廠繭鹹顧夢願膚 獵衊築鹽製繭窪選顧範 (衊選膚願觸鹽簾窪網衊, 265.8) 更多 | - | 2010-01-22 | ||
(Triptorelin) | 糧齋餘鏇衊鏇醖遞淵築(衊窪襯構齋鏇憲衊齋構) = 壓網鏇餘襯餘網鹹願壓 獵衊築鹽製繭窪選顧範 (衊選膚願觸鹽簾窪網衊, 355.6) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用